STAT3 and neoplasm: Other studies using intravenous injections of STAT3 decoy [14, 24] utilized daily, relatively high doses of decoy to effect tumor growth inhibition, highlighting that, as with all nucleic-acid therapeutics, systemic administration is an inefficient strategy for concentrating the therapeutic into tumor tissue and there is a need for more efficient targeted delivery platforms.